Story perspectives

FDA Approves Generic Mifepristone, Sparks Abortion Access Debate

10/12/2025

Summary

Story summary

The U.S. Food and Drug Administration (FDA) approved a generic version of mifepristone on September 30, 2025, to improve access and affordability.
Pro-life advocates, including Ethics & Religious Liberty Commission (ERLC) officials, condemned the approval as undermining women's health and promoting a culture of death.
Reproductive health advocates praised the approval for reproductive autonomy and safety amid ongoing debates about abortion access after the Supreme Court overturned Roe v. Wade.

History

Historical Context

The 1973 Supreme Court ruling in Roe v. Wade established a constitutional right to abortion, striking down many state laws and igniting a national debate on reproductive rights. This landmark decision, based on the Fourteenth Amendment's right to privacy, has shaped political coalitions and legislative actions. The 2022 Dobbs v. Jackson Women's Health Organization ruling overturned Roe, intensifying the ongoing conflict over abortion access in the U.S.

1 of 2

Story summary

The U.S. Food and Drug Administration (FDA) approved a generic version of mifepristone on September 30, 2025, to improve access and affordability.
Pro-life advocates, including Ethics & Religious Liberty Commission (ERLC) officials, condemned the approval as undermining women's health and promoting a culture of death.
Reproductive health advocates praised the approval for reproductive autonomy and safety amid ongoing debates about abortion access after the Supreme Court overturned Roe v. Wade.

1 / 2